Muscle growth drugs could be a game-changer for those seeking weight loss through injections, according to a recent study. The research highlights a potential solution to a common side effect of slimming jabs: the loss of lean body mass. While these injections have proven effective for overweight and obese individuals, experts have raised concerns about the impact on muscle mass and strength.
The study, published in Nature Medicine, introduces apitegromab, a monoclonal antibody that blocks myostatin, a protein responsible for inhibiting muscle growth. This innovative approach aims to counteract the muscle-weakening effects of GLP-1-based drugs like Wegovy and Mounjaro. The trial, funded by the apitegromab producer Scholar Rock, involved 102 participants divided into two groups.
One group received apitegromab alongside tirzepatide (Mounjaro), while the other received a placebo with tirzepatide. After 24 weeks, the results were striking. Participants taking apitegromab retained 55% more lean mass compared to those on the placebo, despite both groups experiencing similar total weight loss. This finding is significant because lean body mass is crucial for physical strength and overall health, burning more calories than fat tissue and reducing the risk of type 2 diabetes.
Professor Alexander Miras, an obesity expert at Ulster University, emphasizes the importance of this discovery. He notes that while GLP-1-based drugs improve functionality, they can also lead to muscle mass and strength loss. This could impact daily activities, such as lifting heavy weights or climbing hills. Apitegromab, therefore, offers a promising solution to enhance functionality without compromising muscle strength.
However, Professor Naveed Sattar from the University of Glasgow, while acknowledging the potential of apitegromab, urges caution. He highlights the need for larger-scale and longer trials to ensure safety and effectiveness. Sattar also emphasizes the importance of increasing physical activity alongside these drugs, framing it as enjoyable and sustainable rather than a medical necessity.
This study opens up exciting possibilities for those seeking weight loss through injections. By addressing the muscle-weakening side effects, apitegromab could revolutionize the way we approach weight loss, making it safer and more sustainable. As research continues, the future of slimming injections may be brighter, offering both effectiveness and muscle preservation.
